Torrent Pharmaceuticals Ltd. - Research Center
500420 TORNTPHARM Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 169.23 | 169.23 | 84.62 | 84.62 | 84.62 |
| Share application money | - | - | - | - | - |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 6,659.53 | 6,286.73 | 6,260.80 | 5,945.48 | 5,036.35 |
| Loan funds | |||||
| Secured loans | 3,332.96 | 4,565.56 | 3,343.41 | 4,384.43 | 3,913.76 |
| Unsecured loans | - | - | - | - | - |
| Total | 10,161.72 | 11,021.52 | 9,688.83 | 10,414.53 | 9,034.73 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 9,880.47 | 9,693.59 | 7,794.90 | 8,135.03 | 8,386.11 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 1,894.55 | 1,721.74 | 1,543.65 | 1,393.79 | 1,188.61 |
| Net block | 7,985.92 | 7,971.85 | 6,251.25 | 6,741.24 | 7,197.50 |
| Capital work-in-progress | 226.23 | 697.93 | 567.50 | 588.11 | 536.41 |
| Investments | 463.31 | 361.21 | 367.64 | 313.92 | 134.89 |
| Net current assets | |||||
| Current assets, loans & advances | 3,701.13 | 3,840.94 | 3,966.17 | 4,117.77 | 4,015.67 |
| Less : current liabilities & provisions | 2,214.87 | 1,850.41 | 1,463.73 | 1,346.51 | 2,849.74 |
| Total net current assets | 1,486.26 | 1,990.53 | 2,502.44 | 2,771.26 | 1,165.93 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 10,161.72 | 11,021.52 | 9,688.83 | 10,414.53 | 9,034.73 |
| Notes: | |||||
| Book value of unquoted investments | 322.27 | 361.18 | 367.64 | 313.92 | 134.87 |
| Market value of quoted investments | - | - | - | - | - |
| Contingent liabilities | 1,395.40 | 1,448.95 | 1,296.42 | 1,155.38 | 325.37 |
| Number of equity sharesoutstanding (Lacs) | 3384.45 | 3384.45 | 1692.23 | 1692.23 | 1692.23 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis